Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1982 1
1983 4
1984 3
1985 3
1986 3
1987 2
1988 3
1989 4
1990 7
1991 9
1992 17
1993 13
1994 13
1995 13
1996 20
1997 19
1998 20
1999 33
2000 41
2001 29
2002 35
2003 33
2004 40
2005 36
2006 43
2007 44
2008 36
2009 42
2010 65
2011 59
2012 79
2013 91
2014 90
2015 86
2016 77
2017 74
2018 93
2019 115
2020 138
2021 92
2022 96
2023 80
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

1,616 results

Results by year

Filters applied: . Clear all
Page 1
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Osmani L, Askin F, Gabrielson E, Li QK. Osmani L, et al. Semin Cancer Biol. 2018 Oct;52(Pt 1):103-109. doi: 10.1016/j.semcancer.2017.11.019. Epub 2017 Nov 26. Semin Cancer Biol. 2018. PMID: 29183778 Free PMC article. Review.
These guidelines emphasize: (1) the subclassification of NSCLC, (2) the critical role of molecular characterization of tumors for targeted therapy, (3) the unique terminology for subclassifying NSCLC using small biopsy specimens, and (4) the utility of IHC biomarkers in the accur …
These guidelines emphasize: (1) the subclassification of NSCLC, (2) the critical role of molecular characterization of tumors for targeted t …
USP51 promotes non-small cell lung carcinoma cell stemness by deubiquitinating TWIST1.
Chen J, Wu Z, Deng W, Tang M, Wu L, Lin N, Chen L, Fu Y, Zhao M, Chen C, Li W. Chen J, et al. J Transl Med. 2023 Jul 8;21(1):453. doi: 10.1186/s12967-023-04304-2. J Transl Med. 2023. PMID: 37422632 Free PMC article.
Colony formation and tumor sphere formation assays were used to assess the stemness of NSCLC cells. A cycloheximide chase time-course assay and a polyubiquitination assay were carried out to analyze the effects of USP51 on the TWIST1 protein level. ...RESULTS: We found tha …
Colony formation and tumor sphere formation assays were used to assess the stemness of NSCLC cells. A cycloheximide chase time-course …
Predictive testing in non-small cell lung carcinoma.
Dundr P, Matěj R, Němejcová K, Bártů M, Stružinská I. Dundr P, et al. Klin Onkol. 2021 Spring;34(Supplementum 1):29-34. doi: 10.48095/ccko2021S29. Klin Onkol. 2021. PMID: 34154327 Review. English.
BACKGROUND: Predictive testing is a crucial part of the complete diagnostic process of non-small cell lung cancer (NSCLC) and a necessary requirement in order to determine proper course of treatment. ...The immunohistochemical evaluation of PD-L1 expression is also …
BACKGROUND: Predictive testing is a crucial part of the complete diagnostic process of non-small cell lung cancer (NSCLC) and a neces …
Exploiting metabolic vulnerabilities of Non small cell lung carcinoma.
Majem B, Nadal E, Muñoz-Pinedo C. Majem B, et al. Semin Cell Dev Biol. 2020 Feb;98:54-62. doi: 10.1016/j.semcdb.2019.06.004. Epub 2019 Jul 2. Semin Cell Dev Biol. 2020. PMID: 31238096 Free article. Review.
Non-Small Cell Lung Carcinoma (NSCLC) is the most common subtype of lung cancer, and the prognosis of NSCLC patients in advanced stages is still very poor. ...
Non-Small Cell Lung Carcinoma (NSCLC) is the most common subtype of lung cancer, and the prognosis of NSCLC patients in advanced stag …
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.
Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Kirson ED, et al. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. doi: 10.1073/pnas.0702916104. Epub 2007 Jun 5. Proc Natl Acad Sci U S A. 2007. PMID: 17551011 Free PMC article. Clinical Trial.
Immunotherapy and Prognosis of Non-small Cell Lung Carcinoma by Monomethoxy polyethylene glycol-hyaluronic acid-platinum Combined with Immune CT4+ and CT8+ Detection.
Ren X, Luo T, Ma H, Zhou M, Yu S. Ren X, et al. Cell Mol Biol (Noisy-le-grand). 2022 Jun 30;68(6):167-173. doi: 10.14715/cmb/2022.68.6.27. Cell Mol Biol (Noisy-le-grand). 2022. PMID: 36227659
The patients in the control group were performed with traditional chemotherapy for 2 treatment courses. The changes in the T-lymphocyte subpopulation before and after the treatment were detected and the therapeutic effects on the patients in the two groups were compared. . …
The patients in the control group were performed with traditional chemotherapy for 2 treatment courses. The changes in the T-lymphocy …
The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
Liu N, Mao J, Tao P, Chi H, Jia W, Dong C. Liu N, et al. Medicine (Baltimore). 2022 Jan 21;101(3):e28617. doi: 10.1097/MD.0000000000028617. Medicine (Baltimore). 2022. PMID: 35060536 Free PMC article.
BACKGROUND: The relationship between neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) and the dire prognosis of non-small cell lung carcinoma patients who received immune checkpoint inhibitors (ICIs) are not k …
BACKGROUND: The relationship between neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ra …
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances.
Dehghani T, Shahrjerdi A, Kahrizi MS, Soleimani E, Ravandeh S, Merza MS, Rahnama N, Ebrahimzadeh F, Bakhshesh M. Dehghani T, et al. Pathol Res Pract. 2023 Jun;246:154470. doi: 10.1016/j.prp.2023.154470. Epub 2023 Apr 20. Pathol Res Pract. 2023. PMID: 37150133 Review.
Moreover, we will take a glimpse into the recently identified predictive biomarkers to determine patients most likely to suffer serious adverse events to decrease untoward toxicity risk and diminish treatment costs....
Moreover, we will take a glimpse into the recently identified predictive biomarkers to determine patients most likely to suffer serio …
ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G, Lu Z, Bi Y, Deng J, Yang X. Hou G, et al. Med Oncol. 2022 Feb 12;39(5):51. doi: 10.1007/s12032-022-01654-7. Med Oncol. 2022. PMID: 35150321
Datamining was also performed to evaluate the ERCC6L mRNA and protein expression levels in patients with LUAD and the correlation with immune cell infiltration. In silico prediction indicated the potential interacting proteins and correlated pathways of ERCC6L in LUAD. ... …
Datamining was also performed to evaluate the ERCC6L mRNA and protein expression levels in patients with LUAD and the correlation with immun …
Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy.
Reungwetwattana T, Eadens MJ, Molina JR. Reungwetwattana T, et al. Semin Respir Crit Care Med. 2011 Feb;32(1):78-93. doi: 10.1055/s-0031-1272872. Epub 2011 Apr 15. Semin Respir Crit Care Med. 2011. PMID: 21500127 Review.
Specific patient subpopulation characteristics (including EGFR mutations) may be prognostically important to identify potential responders (or nonresponders) to therapy. ...
Specific patient subpopulation characteristics (including EGFR mutations) may be prognostically important to identify potential respo …
1,616 results